At a glance
ClinicalIndex Comparison RecordPhase 1Not Yet Recruiting· 60 target
Drug / intervention
Cemiplimab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Randomized Trial of Induction Cemiplimab With or Without Fianlimab in De-escalated Chemoradiation for Locoregionally Advanced Non-Metastatic Nasopharyngeal Carcinoma
In Brief
A Phase 1 clinical trial evaluating Cemiplimab and Fianlimab for Nasopharyngeal Carcinoma and 3 related conditions. Not yet recruiting, targeting 60 participants across 7 sites.
Detailed Summary
The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin before standard chemoradiation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Carcinoma, Nasopharynx Cancer
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals
Timeline
Phase 1Not Yet Recruiting
2027202820292030
First PostedJun 2026
Enrollment StartJul 2026
TodayJul 2026
Primary CompletionJul 2030
First PostedJun 16, 2026
Enrollment StartJul 1, 2026
Primary CompletionJul 1, 2030
TodayJul 1, 2026
Enrollment to primary: 4 yearsPosted 15 days agoPrimary completion in 4 years
Interventions
Cemiplimabdrug
Cemiplimab (LIBTAYO) is a PD-1 blocking antibody
Fianlimabdrug
Fianlimab is a fully human monoclonal antibody targeting the immune checkpoint receptor LAG-3 on T cells